Skip to Content
Merck

C8772

Cholera filtrate

lyophilized powder, bacterial sialidase receptor-destroying enzyme (RDE)

Synonym(s):

Cholera Filter

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352200
NACRES:
NA.77
Form:
lyophilized powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Cholera filtrate, lyophilized powder

form

lyophilized powder

Quality Level

storage temp.

2-8°C

General description

Cholera filtrate promotes the activation of adenylate cyclase. It does not affect the activity of cyclic adenosine monophosphate (cAMP) phosphodiesterase.

Application

Cholerafiltrate has been used as a receptor destroying enzyme (RDE): inhemagglutination inhibition assay of serum samples, in microneutralizationassay of mice serum samples, in hemagglutination inhibition assay to removenon-specific inhibitors from the cell culture supernatant samples

Biochem/physiol Actions

Cholera filtrate is a bacterial sialidase receptor-destroying enzyme (RDE) and may be used as crude neuraminidase. It may also be used in serological testing for influenza.

Preparation Note

After reconstituting with 5ml sterile water, it will contain 0.01% MIT as preservative.

Other Notes

See a separate listing of neuraminidase for preparations showing higher activity.

Disclaimer

For research use only. Not for use in diagnostic procedures.


signalword

Danger

flash_point_f

Not applicable

flash_point_c

Not applicable

supp_hazards

Hazard Classifications

Aquatic Chronic 2 - Eye Dam. 1 - Skin Corr. 1A - Skin Sens. 1

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
Daniela M, et al.
Nature Communications (2024)
WHO Tech Rep. Serv.
WHO Expert Committee on Influenza, 64 (1953)
A Riccomi et al.
Vaccines, 12(4) (2024-04-27)
A number of studies have suggested that influenza vaccination can provide protection against COVID-19, but the underlying mechanisms that could explain this association are still unclear. In this study, the effect of the 2021/2022 seasonal influenza vaccination on the immune



Global Trade Item Number

SKUGTIN
C8772-1VL04061838445681